Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. more
Time Frame | PBM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.84% | 0.49% | -0.42% |
1-Month Return | -17.87% | -3.1% | -2.2% |
3-Month Return | -75.09% | -8.59% | 2.38% |
6-Month Return | -92.89% | -4.57% | 5.1% |
1-Year Return | -99.8% | -0.94% | 23.79% |
3-Year Return | -99.77% | 2.88% | 26.66% |
5-Year Return | -99.77% | 35.84% | 81.16% |
Mar '22 | Mar '23 | Mar '24 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] | ||
Cost of Revenue | - | - | 240.00 | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":100,"profit":true}] | ||
Gross Profit | - | - | (240.00) | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":-24000,"profit":false}] | ||
Gross Margin | - | - | (Infinity%) | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":null,"profit":false}] | ||
Operating Expenses | 334.29K | 1.29M | 2.75M | [{"date":"2022-03-31","value":12.15,"profit":true},{"date":"2023-03-31","value":47.03,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] | ||
Operating Income | (334.29K) | (1.29M) | (2.75M) | [{"date":"2022-03-31","value":-33429000,"profit":false},{"date":"2023-03-31","value":-129398000,"profit":false},{"date":"2024-03-31","value":-275182500,"profit":false}] | ||
Total Non-Operating Income/Expense | 8.56M | 9.31M | (48.46M) | [{"date":"2022-03-31","value":92,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":-520.5,"profit":false}] | ||
Pre-Tax Income | 8.23M | 8.01M | (51.16M) | [{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":97.37,"profit":true},{"date":"2024-03-31","value":-621.58,"profit":false}] | ||
Income Taxes | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] | ||
Income After Taxes | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] | ||
Income From Continuous Operations | (1.86M) | (3.21M) | (51.16M) | [{"date":"2022-03-31","value":-185823495,"profit":false},{"date":"2023-03-31","value":-320640300,"profit":false},{"date":"2024-03-31","value":-5115904700,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] | ||
Net Income | 8.23M | 8.01M | (51.16M) | [{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":97.37,"profit":true},{"date":"2024-03-31","value":-621.58,"profit":false}] | ||
EPS (Diluted) | 26.83 | 12.39 | - | [{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":46.19,"profit":true},{"date":"2024-03-31","value":"-","profit":true}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
PBM | |
---|---|
Cash Ratio | 0.06 |
Current Ratio | 0.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PBM | |
---|---|
ROA (LTM) | -126.35% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PBM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 10.69 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -9.69 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PBM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Psyence Biomedical Ltd. Common Shares (PBM) share price today is $1.7
Yes, Indians can buy shares of Psyence Biomedical Ltd. Common Shares (PBM) on Vested. To buy Psyence Biomedical Ltd. Common Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PBM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Psyence Biomedical Ltd. Common Shares (PBM) via the Vested app. You can start investing in Psyence Biomedical Ltd. Common Shares (PBM) with a minimum investment of $1.
You can invest in shares of Psyence Biomedical Ltd. Common Shares (PBM) via Vested in three simple steps:
The 52-week high price of Psyence Biomedical Ltd. Common Shares (PBM) is $945.15. The 52-week low price of Psyence Biomedical Ltd. Common Shares (PBM) is $1.51.
The price-to-earnings (P/E) ratio of Psyence Biomedical Ltd. Common Shares (PBM) is
The price-to-book (P/B) ratio of Psyence Biomedical Ltd. Common Shares (PBM) is 0.00
The dividend yield of Psyence Biomedical Ltd. Common Shares (PBM) is 0.00%
The market capitalization of Psyence Biomedical Ltd. Common Shares (PBM) is $7.53M
The stock symbol (or ticker) of Psyence Biomedical Ltd. Common Shares is PBM